PROSTATE PET/CT ORDER FORM

SCHEDULING

P: 561.496.6935 F: 561.496.6936

See back for addresses

If faxing an order, please include:

DemographicsInsurance card

d • Clinical notes



		Check-in time	Patient DOB		OM OF
Patient name (as shown on insurance card)		Primary phone #	Secondary phone #		phone #
Insurance name		Insurance ID #	Authorization #		
O Private O Government O No insurar	nce Isotope O Pylarify PSMA PET/CO Axumin O FDG	T O Illuccix PSMA O 1st A	Available PSMA Diag	nosis O C61 I O R97.2 O Othe	Malignant Neoplasm of Prostat 21 Rising PSA r
(REQUIRED) Written diagnosis/reason/sv	mptom for exam(s). Must include	specific clinical	Clinical Decision Support (CDS)		
REQUIRED) Written diagnosis/reason/symptom for exam(s). Must included in the case of the c		each test.	Required for Medicare Part B Modifier (determination) G-code (vendor)		
Is the exam/procedure related to an inju	ry? O No O Yes If yes O Initial C	Subsequent or O Sequela			
REQUIREMENT	S FOR NEWLY DIA	AGNOSED PR	OSTATE C	ANCE	R PET/CT
 PSMA isotopes only approved for initial stag 	jing: PYLARIFY OR ILLUCCIX				
Patient must be NCCN Guidelines Unfavorab	ble intermediate risk for insurance rec	uirement with a MINIMUM	OF 2 INTERMEDIATI	RISK FACTO	RS.
Biopsy results: cores pos	itive out of total co	res. Intermediate Risk F	ACTOR is greater tha	n 50% positi	ve.
		Please send biopsy resul	lts.		
• Date of biopsy		, ,	lts.		
Date of biopsy Date	INTERMEDIATE RISK FACTOR is	PSA>10ng/dL		ACTOR is Gle	eason 4+3.
Date of biopsy Date	INTERMEDIATE RISK FACTOR is Must be greater than 4 +	PSA>10ng/dL 3 for insurance approval. I	NTERMEDIATE RISK I		
PSA Date Gleason score: + REQUIREMENTS F Approximate date of prostate cancer diagnose	INTERMEDIATE RISK FACTOR is Must be greater than 4 + FOR RECURRENT sis	PSA>10ng/dL 3 for insurance approval. I	NTERMEDIATE RISK I	CAN	CER PET/CT
PSA Date	INTERMEDIATE RISK FACTOR is Must be greater than 4 + FOR RECURRENT sis reatment? O Yes O No If YES, chool therapy O Chemotherapy O Proton	PSA>10ng/dL 3 for insurance approval. II DIAGNOSED ose type of treatment(s) and	NTERMEDIATE RISK I	CAN	CER PET/CT
PSA Date	INTERMEDIATE RISK FACTOR is Must be greater than 4 + FOR RECURRENT sis reatment? O Yes O No If YES, chooseherapy O Chemotherapy O Proton	PSA>10ng/dL 3 for insurance approval. II DIAGNOSED ose type of treatment(s) and beam O HIFU	NTERMEDIATE RISK I	CAN	CER PET/CT
PSA Date	INTERMEDIATE RISK FACTOR is	PSA>10ng/dL 3 for insurance approval. II DIAGNOSED Disc type of treatment(s) and beam O HIFU nths)	PROSTATI proceed. If active sur	veillance, sto	OP, does not meet study
PSA Date	INTERMEDIATE RISK FACTOR is	PSA>10ng/dL 3 for insurance approval. II DIAGNOSED Disc type of treatment(s) and beam O HIFU nths)	PROSTATI proceed. If active sur	veillance, sto	OP, does not meet study
PSA Date	INTERMEDIATE RISK FACTOR is Must be greater than 4 + FOR RECURRENT sis reatment? O Yes O No If YES, chood therapy O Chemotherapy O Proton and levels (most recent is within 3 modeling the parts) Date: Date:	PSA>10ng/dL 3 for insurance approval. II DIAGNOSED DIAGNOSED Disc type of treatment(s) and beam O HIFU Inths)	PROSTATI proceed. If active sur	E CAN	OP, does not meet study
Date of biopsy PSA Date Gleason score: + REQUIREMENTS F Approximate date of prostate cancer diagnors that the patient completed prostate cancer to O Surgery O Prostatectomy O Radiation to Approximate date treatment was completed Two most recent PSA post treatment dates are serious processes.	INTERMEDIATE RISK FACTOR is Must be greater than 4 + FOR RECURRENT sis reatment? O Yes O No If YES, chood therapy O Chemotherapy O Proton and levels (most recent is within 3 mo Date: Date: and the second most recent PSA? O's scan or CT first. For Axumin it is typical.	PSA>10ng/dL 3 for insurance approval. II DIAGNOSED Disc type of treatment(s) and beam O HIFU nths) (es, proceed O No, stop, day required. Just send requised.	PROSTATI proceed. If active surfaces not meet study of	E CAN	OP, does not meet study

- 1. Once all criteria are met and the order and documentation are received, RAYUS Radiology will call the patient to schedule the study.
- 2. Once scheduled, when appropriate the patient must sign an ABN, a cancellation policy and a consent to charge credit card for the dose deposit. This must be done a minimum of 48 hours prior to the study via fax or onsite at one of our locations.
- 3. Please contact your insurance company for cost. The dose can only be used once, for this one patient. Credit card, debit and check accepted. Payment plan for no-show is required.
- 4. The patient must check-in at arrival time to avoid dose decay.
- 5. The patient must cancel by 12:00 PM the day prior to the study to avoid being charged for the drug. Voicemail cancellation is not sufficient.

Patient consideration O Arrange transportation						
REPORTING METHOD	O Report only via fax	O Provider portal	O CD with patient			
Provider name (print)	Provider location City/Zip	Phone #	Fax #			
Provider signature (required) Do not use rubber stamp.		NPI # (required for new provide	rs) Date			



BOCA RATON

8142 Glades Rd. Boca Raton, FL 33434

BOCA RATON WEST

23071 State Rd. 7 Boca Raton, FL 33428

BOYNTON BEACH EAST

1425 Gateway Blvd., Ste 100 Boynton Beach, FL 33426

BOYNTON BEACH WEST

6080 Boynton Beach Blvd., Ste 140 Boynton Beach, FL 33437

DELRAY BEACH

15340 Jog Rd., Ste 160 Delray Beach, FL 33446

PALM BEACH GARDENS

3601 PGA Blvd., Ste 100 Palm Beach Gardens, FL 33410

WELLINGTON

2565 S. State Rd. 7 Wellington, FL 33414

WELLINGTON WOMEN'S CARE

2863 State Road 7, Ste 400 Wellington, FL 33414

WEST PALM BEACH

1572 Palm Beach Lakes Blvd., Ste 2 West Palm Beach, FL 33401

